Related Experiment Video

Updated: Jun 20, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

[Research Progress on Predictive Biomarkers of Immunotherapy Efficacy
in Non-small Cell Lung Cancer]

Tiansheng Sun1, Zhang Chen1, Kunchen Wei1

  • 1Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Naval Medical University,
Shanghai 200003, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|July 19, 2024
PubMed

Insights

Identifying reliable biomarkers is crucial for predicting non-small cell lung cancer (NSCLC) patient response to immune checkpoint inhibitors (ICIs). This review explores biomarkers to guide precision immunotherapy for improved patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
  • Immune checkpoint inhibitors (ICIs) have revolutionized NSCLC treatment, but response rates vary significantly.
  • Predictive biomarkers are needed to optimize ICI therapy selection and patient outcomes.

Purpose of the Study:

  • To review and synthesize current knowledge on predictive biomarkers for immunotherapy efficacy in NSCLC.
  • To provide guidance for the clinical application of precision immunotherapy in NSCLC.

Main Methods:

  • Comprehensive literature review of studies on biomarkers for ICI treatment in NSCLC.
  • Analysis of molecular biology and genomic sequencing data related to tumor immune microenvironment.
  • Focus on biomarkers associated with patient response and prognosis.

Main Results:

  • Emerging biomarkers show promise in predicting response to ICI therapy.
  • Understanding the tumor immune microenvironment is key to biomarker discovery.
  • No single biomarker currently guarantees prediction of treatment success.

Conclusions:

  • Reliable predictive biomarkers are essential for personalized immunotherapy in NSCLC.
  • Continued research into novel biomarkers will enhance treatment selection and patient benefit.
  • Precision immunotherapy holds significant potential for improving NSCLC patient prognosis.
Keywords:
BiomarkerImmunotherapyLung neoplasmsPrognosticationTumor mutational burden

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K